Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17239733 | 1.00 | PPM1D (0.31) | PPM1D | |
| SCHEMBL29819863 | 1.00 | PPM1D (0.31) | PPM1D | |
| SCHEMBL17249868 | 0.79 | NPSR1 (0.35) | — | |
| SCHEMBL31705527 | 0.72 | — | — | |
| SCHEMBL18775110 | 0.72 | — | — | |
| SCHEMBL31706105 | 0.70 | NOS3 (0.41) | — | |
| SCHEMBL10609389 | 0.70 | NPSR1 (0.37) | — | |
| SCHEMBL10609396 | 0.70 | NPSR1 (0.37) | — | |
| SCHEMBL3430646 | 0.69 | — | — | |
| SCHEMBL17762361 | 0.67 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-09-24 | — | — | US | disclosed |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-07-21 | — | — | US | disclosed |
| CN-106458976-B | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | 百时美施贵宝公司 | 2020-05-22 | — | — | CN | disclosed |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-18 | — | — | US | disclosed |
| US-10017497-B2 | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-12 | — | — | US | disclosed |
| EP-3140296-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3140297-B1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL MYERS SQUIBB CO (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9873679-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170217930-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-23 | — | — | US | disclosed |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299267-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | PPM1D 1670/4885 |
| US-20170081282-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-10301260-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-20190112293-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-10717725-B2 | Pyrrolidine GPR40 modulators | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-20180099949-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
| US-10017497-B2 | Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes | GPR55, GPR65, GPR4 | PPM1D 1561/4885 |
| US-20170217930-A1 | PYRROLIDINE GPR40 MODULATORS FOR THE TREATMENT OF DISEASES SUCH AS DIABETES | GPR55, GPR65, GPR4 | PPM1D 1561/4885 |
| US-20150322044-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR4 | PPM1D 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.